Andrew Tsai
Stock Analyst at Jefferies
(0.47)
# 3,968
Out of 4,868 analysts
20
Total ratings
29.41%
Success rate
-33.19%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andrew Tsai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Maintains: Buy | $125 → $54 | $20.77 | +159.99% | 2 | Jun 16, 2025 | |
| VRNA Verona Pharma | Maintains: Buy | $95 → $110 | $90.92 | +20.99% | 1 | Jun 11, 2025 | |
| RCKT Rocket Pharmaceuticals | Downgrades: Hold | $29 → $2.5 | $2.83 | -11.66% | 2 | May 28, 2025 | |
| AXSM Axsome Therapeutics | Initiates: Buy | $200 | $102.90 | +94.37% | 1 | Apr 7, 2025 | |
| BEKE KE Holdings | Maintains: Overweight | $19 → $27 | $18.13 | +48.92% | 2 | Mar 19, 2025 | |
| RLMD Relmada Therapeutics | Upgrades: Buy | $3.5 → $13 | $0.68 | +1,806.44% | 2 | Sep 17, 2024 | |
| RAPP Rapport Therapeutics | Initiates: Buy | $35 | $11.02 | +217.60% | 1 | Jul 2, 2024 | |
| ANRO Alto Neuroscience | Initiates: Buy | $33 | $2.27 | +1,353.74% | 1 | Feb 27, 2024 | |
| VTGN Vistagen Therapeutics | Upgrades: Buy | $0.2 → $15 | $2.06 | +628.16% | 2 | Dec 7, 2023 | |
| LXRX Lexicon Pharmaceuticals | Initiates: Hold | $3 | $0.75 | +302.41% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $32 → $3 | $0.31 | +867.74% | 2 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $7.92 | +152.53% | 1 | Feb 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $2.33 | +1,058.80% | 1 | Sep 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $16 → $23 | $31.90 | -27.90% | 1 | Jun 1, 2020 |
Sarepta Therapeutics
Jun 16, 2025
Maintains: Buy
Price Target: $125 → $54
Current: $20.77
Upside: +159.99%
Verona Pharma
Jun 11, 2025
Maintains: Buy
Price Target: $95 → $110
Current: $90.92
Upside: +20.99%
Rocket Pharmaceuticals
May 28, 2025
Downgrades: Hold
Price Target: $29 → $2.5
Current: $2.83
Upside: -11.66%
Axsome Therapeutics
Apr 7, 2025
Initiates: Buy
Price Target: $200
Current: $102.90
Upside: +94.37%
KE Holdings
Mar 19, 2025
Maintains: Overweight
Price Target: $19 → $27
Current: $18.13
Upside: +48.92%
Relmada Therapeutics
Sep 17, 2024
Upgrades: Buy
Price Target: $3.5 → $13
Current: $0.68
Upside: +1,806.44%
Rapport Therapeutics
Jul 2, 2024
Initiates: Buy
Price Target: $35
Current: $11.02
Upside: +217.60%
Alto Neuroscience
Feb 27, 2024
Initiates: Buy
Price Target: $33
Current: $2.27
Upside: +1,353.74%
Vistagen Therapeutics
Dec 7, 2023
Upgrades: Buy
Price Target: $0.2 → $15
Current: $2.06
Upside: +628.16%
Lexicon Pharmaceuticals
Mar 7, 2023
Initiates: Hold
Price Target: $3
Current: $0.75
Upside: +302.41%
Jun 23, 2022
Downgrades: Hold
Price Target: $32 → $3
Current: $0.31
Upside: +867.74%
Feb 1, 2022
Initiates: Buy
Price Target: $20
Current: $7.92
Upside: +152.53%
Sep 1, 2021
Initiates: Buy
Price Target: $27
Current: $2.33
Upside: +1,058.80%
Jun 1, 2020
Assumes: Buy
Price Target: $16 → $23
Current: $31.90
Upside: -27.90%